Get to know our clinical trials
Clinical trial of ADP-A2M4CD8 in HLA-A2 patients with MAGE-A4-expressing tumors.
THE OBJECTIVE IS TO EVALUATE THE SAFETY AND EFFICACY OF ADP-A2M4CD8 IN HLA-A2 PATIENTS WITH MAGE-A4-EXPRESSING TUMORS.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ADP-A2M4CD8 IN HLA-A2 PATIENTS WITH MAGE-A4-EXPRESSING TUMORS.
- Code EudraCT: 2019-001965-34
- Protocol number: ADP-0055-001
- Promoter: Adaptimmune LLC
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.